A 34-year-old woman was newly diagnosed with HIV on a routine screening test about 4 months ago. Her baseline CD4 count was 573 cells/mm3. At her initial clinic visit she had a non-fasting lipid panel obtained, and it was normal. She started on antiretroviral therapy 4 months ago and now has an undetectable HIV RNA level. She had a non-fasting lipid panel repeated 3 weeks ago and again it was normal. She does not smoke, she does not have diabetes, her blood pressure is normal, and she does not have a strong family history of cardiovascular disease.
Assuming the lipid panel continues to remain normal, based on recommendations in the Adult and Adolescent ART Guidelines, which one of the following is the recommended approach for monitoring the lipid profile in this woman at this point?
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
January 27th, 2025
January 27th, 2025
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5
Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine Edurant